Fusion AntibodiesLSE:FAB -4.35%33 PS Ratio is 7.86 as of Jul. 10, 2026, which is 56% above its 10-year median of 5.03. GuruFocus rates LSE:FAB with a GF Score™ of 33/100 and a GF Value™ of £0.04 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 930 Biotechnology companies, Fusion Antibodies ranks better than 56.34% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Fusion Antibodies's share price is £0.11.
Fusion Antibodies's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2025 was £0.01. Hence, Fusion Antibodies's PS Ratio for today is 7.86.
The historical rank and industry rank for Fusion Antibodies's PS Ratio or its related term are showing as below:
LSE:FAB'
s PS Ratio Range Over the Past 10 Years
Min: 0.29 Med: 5.03 Max: 24.48
Current: 7.53
During the past 11 years, Fusion Antibodies's highest PS Ratio was 24.48. The lowest was 0.29. And the median was 5.03.
LSE:FAB's PS Ratio is ranked better than 56.34% of 930
companies
in the Biotechnology industry
Industry Median: 9.515
vs LSE:FAB: 7.53
Fusion Antibodies PLC revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Fusion Antibodies was -26.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -52.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -39.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -6.10% per year.
During the past 11 years, Fusion Antibodies's highest 3-Year average Revenue per Share Growth Rate was 59.70% per year. The lowest was -52.40% per year. And the median was 6.65% per year.
Back to Basics: PS Ratio
Fusion Antibodies (LSE:FAB) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Fusion Antibodies PS Ratio Related Terms
Fusion Antibodies PS Ratio Historical Data
* Premium members only.
The historical data trend for Fusion Antibodies's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fusion Antibodies's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Antibodies PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Antibodies's PS Ratio distribution charts can be found below:
* The bar in red indicates where Fusion Antibodies's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Fusion Antibodies's Share Price of today is £0.11.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fusion Antibodies's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2025 was £0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Fusion Antibodies (LSE:FAB) has a PS Ratio of 7.86 as of Jul. 10, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Fusion Antibodies and its competitors. This is 56% above median its historical median of 5.03. Over the past decade, Fusion Antibodies' PS Ratio has ranged from 0.29 to 24.48. According to the industry distribution chart, Fusion Antibodies ranks #406 out of 930 companies in the Biotechnology industry, placing it in the top 43.7%.
Is Fusion Antibodies' PS Ratio too high?
Fusion Antibodies' current PS Ratio of 7.86 is 56% above median its 10-year median of 5.03. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 24.48. The Biotechnology industry median PS Ratio is 9.52. Fusion Antibodies' value of 7.86 is 17.4% below this industry median. Based on the distribution chart, Fusion Antibodies ranks #406 out of 930 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fusion Antibodies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fusion Antibodies ranks #406 out of 930 companies for PS Ratio. This puts Fusion Antibodies in the upper half of its industry. The industry median PS Ratio is 9.52. Fusion Antibodies' value of 7.86 is 17.4% below this benchmark. Historically, Fusion Antibodies' own PS Ratio has ranged from 0.29 to 24.48 over the past decade. While the company's 10-year median is 5.03 vs. the industry median of 9.52, Fusion Antibodies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fusion Antibodies's current PS Ratio of 7.86 is 17.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Fusion Antibodies and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fusion Antibodies's current PS Ratio is 7.86, which is 56% above median its own 10-year median of 5.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.11 — trading 175% above its estimated fair value. The current PS Ratio is 7.86, which is 56% above median its 10-year median of 5.03 and 17.4% below the Biotechnology industry median of 9.52. Fusion Antibodies' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current PS Ratio is 7.86 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?
Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued.
The current stock price of £0.11 is trading 175% above its estimated GF Value™ of £0.04.
GuruFocus considers Fusion Antibodies to be Significantly Overvalued.
Key valuation signals for LSE:FAB:
PS Ratio: 7.86 (56% above median its 10-year median of 5.03)
GF Value™: £0.04 vs. price of £0.11 (175% above fair value)
Industry Position: 17.4% below the Biotechnology median (#406 of 930)
No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
33GF Score
Get the complete analysis for LSE:FAB
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
